Neuropathy in a rat model of mild diabetes induced by multiple low doses of streptozotocin: effects of the antioxidant stobadine in comparison with a high-dose alpha-lipoic acid treatment.
Hyperglycaemia-induced oxidative stress makes an important contribution to the aetiology of diabetic neuropathy. The aim of our study was to evaluate the effect of the antioxidant stobadine (STB) in comparison with a treatment by a high-dose of alpha-lipoic acid (ALA), on the neurological consequences of chronic hyperglycaemia in an animal model of diabetes in Wistar rats (16 weeks old), made diabetic by streptozotocin (STZ 3 x 20 mg i.v.). Neuropathy was evaluated electrophysiologically by measuring motor nerve conduction velocity (NCV) in the 4th and 8th week in vivo and motor NCV and resistance to ischaemic conduction failure (RICF) of the sciatic nerve in the 10th week of the experiment in vitro. The therapy with ALA (100 mg/kg i.p., 5 times a week) and STB (25 mg/kg i.p., 5 times a week) had a significant effect on NCV in vivo in the 8th week of the experiment and no effect in the 10th week in vitro. The RICF elevated in diabetic animals was significantly modified by ALA. The effect of the antioxidant STB on NCV was comparable with that of ALA, while RICF was affected only by ALA. We conclude that treatment with appropriate antioxidants might partially prevent nerve dysfunction in diabetic rats.
Skalská
Silvia
S
Institute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, Bratislava, Slovakia. silvia.skalska@yahoo.com
Kucera
Pavol
P
Goldenberg
Zoltán
Z
Stefek
Milan
M
Kyselová
Zuzana
Z
Jariabka
Pavol
P
Gajdosíková
Alena
A
Klobucníková
Katarína
K
Traubner
Pavel
P
Stolc
Svorad
S
D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage; D002243:Carbolines / Q000008:administration & dosage*; D003929:Diabetic Neuropathies / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology*; D004195:Disease Models, Animal; D006801:Humans; D008297:Male; D009431:Neural Conduction / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin; D008063:Thioctic Acid / Q000008:administration & dosage; D016896:Treatment Outcome
D000975:Antioxidants; D002243:Carbolines; D013311:Streptozocin; D008063:Thioctic Acid; C100106:dicarbine